Announcement PDF Antisense Therapeutics ATL1102 for Multiple Sclerosis Early Access Program Forward Looking Statements This presentation contains forward-looking statements regarding the Company’s business and the therapeutic and commercial potential of its technologies and products in development. Any statement describing the Company’s goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the process of discovering, developing and commercializing drugs that can be proven to be safe and effective for use as human therapeutics, and in the endeavor of building a business around such products and services. Actual results could differ materially from those discussed in this presentation. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the Antisense Therapeutics Limited Annual Report for the year ended 30 June 2014 and the report for Half Year ending 31 December 2014, copies of which are available from the Company or at www.antisense.com.au. THIS PRESENTATION IS FOR THE AUSTRALIAN MARKET ONLY This presentation has been prepared in connection with the obligations of Antisense Therapeutics under Listing Rules of the Australian Securities Exchange. Early Access Program (EAP) EAP offers patients access to new non-registered pharmaceuticals • Products may be provided to patients with a life threatening or debilitating disease where no alternative or appropriate therapy exists • > 1,000,000 patients annually in Europe alone are left without treatment options with only a small percentage able to access new therapies via clinical trials1 • Can charge for drug access in certain markets • Product must have been in Phase 2 trials or later and have shown evidence of efficacy EAP Pricing • Pricing set by the Sponsor (ANP) at comparable price to registered products • MS treatment costs in Europe range from A$25,000–$33,000 per patient per year2 1 Estimated by myTomorrows 2 Pricing for Tysabri, Gilenya, & Tecfidera -Toumi M and Jadot G in J. Market Access and Health Policy 2014, 2: 23932 EAP in Europe for ATL1102 MS Market • 400,000 people with MS in Europe and more than 1,000,000 world wide • Significant number of patients do not properly respond to existing therapies suggesting a pool of possible candidates for use of ATL1102 under the EAP conditions EAP Establishment for ATL1102 • Partnering Agreement signed with EAP specialists myTomorrows • myTomorrows to perform EAP activities at their cost including data collection and seeking EAP approvals initially in Europe in those markets where drug use is reimbursed • ANP to provide ATL1102 product for use in the EAP • Arrangements being established to source ATL1102 from existing 3rd party supplies (2 batches) for potential use in the EAP • Proposal to initially source one batch of ATL1102 to commence the EAP • Subject to this first batch of material being confirmed (through retesting) as of suitable quality for use in the EAP, the quantity of material is expected to be sufficient for one year’s treatment for over 150 patients at the 200mg/week dose • Material could be available as early as 4’Q’15 for use in the EAP • Possible cash flow positive income myTomorrows PROVIDING EARLY ACCESS TO DRUGS IN DEVELOPMENT myTomorrows is creating freedom of choice for physicians and patients with unmet medical needs by offering earlier access to medicines that show promising results during clinical trials, but are not officially registered yet. With the support of their doctors, patients who suffer from cancer, a neurological disorder, a rare disease or a severe depression, can have earlier access to such medicines. myTomorrows identifies innovative drugs, informs physicians and patients and facilitates requests for access to these drugs in development via a world-wide Internet-based platform. For more information about myTomorrows, please visit the website www.mytomorrows.com. ATL1102 Multiple Sclerosis ATL1102 for Multiple Sclerosis • Multiple Sclerosis (MS) is a chronic, progressive, and debilitating autoimmune disease that affects central nervous system, brain and spinal cord • Global sales for MS drugs in 2013 were US$14 Billion • ATL1102 is an antisense inhibitor of VLA-4 protein a clinically validated target in MS • Successful Phase II trial completed in patients with Relapsing Remitting-MS • Met primary end point after only two months of dosing reducing the cumulative number of new active brain lesions by 54.4% (p=0.01) compared to placebo Phase II trial results published in Neurology Project Status: ATL1102 for MS • US and EU patent allowances extending patent protection to 2029 • Positive response received from FDA on Pre-IND assessment for a Phase IIb trial • Phase IIa trial results published in the Journal of the American Academy of Neurology • Engaged in the process to attract a pharmaceutical company partner to undertake the Phase IIb trial • Early Access Program now established initially for use of ATL1102 in Europe Antisense Therapeutics Mark Diamond, CEO +61 (3) 9827 8999